Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (601-610 of 643) with videos related to

Pageof 65
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
The New England Journal of Medicine|January 18, 2023
Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
Nature Communications|May 30, 2014
A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Cancer Discovery|January 12, 2020
Characteristics and Outcome of <i>AKT1</i> <sup>E17K</sup>-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic RegistryLillian M Smyth, Qin Zhou, Bastien Nguyen, et al.
Cell Reports. Medicine|October 31, 2025
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profilingPavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, et al.
Pageof 65

Showing results (601-610 of 643) with videos related to

Sort By:
Pageof 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
The New England Journal of Medicine|January 18, 2023
Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
Nature Communications|May 30, 2014
A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Cancer Discovery|January 12, 2020
Characteristics and Outcome of <i>AKT1</i> <sup>E17K</sup>-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic RegistryLillian M Smyth, Qin Zhou, Bastien Nguyen, et al.
Cell Reports. Medicine|October 31, 2025
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profilingPavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, et al.
Pageof 65